Comparison of a pediatric-inspired treatment protocol versus standard-intensity chemotherapy for young adults with standard-risk BCR-ABL negative acute lymphoblastic leukemia

References

• Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007;109:896–904.
   PubMed Web of Science ®Google Scholar
• Möricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111:4477–4489.
   PubMed Web of Science ®Google Scholar
• Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM 2000 study. Blood. 2009;115:3206–3214.
   Web of Science ®Google Scholar
• Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children's Oncology Group. J Clin Oncol. 2012;30:1663–1669.
   PubMed Web of Science ®Google Scholar
• Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 2002;99:863–871.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, O’Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone (Hyer-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101:2788–2801.
   PubMed Web of Science ®Google Scholar
• Thomas X, Boiron J, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22:4075–4086.
   PubMed Web of Science ®Google Scholar
• Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106:3760–3767.
   PubMed Web of Science ®Google Scholar
• Boissel N, Auclerc M, Lhéritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21:774–780.
   PubMed Web of Science ®Google Scholar
• Ribera J, Oriol A, Sanz M, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96. J Clin Oncol. 2008;26:1843–1849.
   PubMed Web of Science ®Google Scholar
• Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAAL-2003 Study. J Clin Oncol. 2009;27:911–918.
   PubMed Web of Science ®Google Scholar
• Storring JM, Minden MD, Kao S, et al. Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. Br J Haematol. 2009;146:76–85.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015;29:526–534.
   PubMed Web of Science ®Google Scholar
• Abou Mourad YR, Bhargava R, Bruyère H, et al. Normal karyotype CALLA-positive adult pre-B ALL: dismal outcome with chemotherapy for patients with loss/gain of ABL1 and/or BCR FISH signals. Clin Lymphoma Myeloma Leuk. 2013;13:281–286.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Stevenson KE, Neuberg DS, et al. A multicenter phase II study using a dose intensified pegylated-asparaginase pediatric regimen in adults with untreated acute lymphoblastic leukemia: a DFCI ALL Consortium trial [abstract]. Blood. 2015;126: Abstract 80. Available from: http://www.bloodjournal.org/content/126/23/80
   Web of Science ®Google Scholar
• Ram R, Wolach O, Vidal L, et al. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis. Am J Hematol. 2012;87:472–478.
   PubMed Web of Science ®Google Scholar
• Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109:944–950.
   PubMed Web of Science ®Google Scholar
• Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371:1005–1015.
   PubMed Web of Science ®Google Scholar
• Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of residual disease (MRD) in acute lymphoblastic leukemia (ALL). Blood. 2009;113:4153–4162.
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Kneba M, Raff T, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012;120:1868–1876.
   PubMed Web of Science ®Google Scholar
• Schrappe M, Reiter A, Ludwig W, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000;95:3310–3322.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute [Internet]. Combination chemotherapy in treating young patients with newly diagnosed acute lymphoblastic leukemia [cited 2015 Nov 27]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT00558519?term=calgb+and +10403&rank =1&show_desc=Y#desc.
   Google Scholar
• Australasian Leukemia and Lymphoma Group [Internet]. A multicentre trial for the treatment of adolescents aged 15 years and above, and young adults aged up to 40 years, with newly diagnosed acute lymphoblastic leukemia (ALL) [cited 2015 Nov 27]. Available from: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id =343008&isReview=true.
   Google Scholar